标题
MAP kinase signaling and inhibition in melanoma
作者
关键词
-
出版物
ONCOGENE
Volume 32, Issue 19, Pages 2373-2379
出版商
Springer Nature
发表日期
2012-09-03
DOI
10.1038/onc.2012.345
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma.
- (2017) K. T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.
- (2017) J. Delord et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.
- (2017) J. R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436).
- (2017) K. L. Nathanson et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma
- (2015) William D. Tap et al. NEOPLASIA
- Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
- (2015) Elisabetta Vergani et al. NEOPLASIA
- Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)
- (2012) K. A. Margolin et al. CLINICAL CANCER RESEARCH
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression
- (2011) J Lin et al. BRITISH JOURNAL OF CANCER
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- ERK and PDE4 cooperate to induce RAF isoform switching in melanoma
- (2011) Amélie Marquette et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Resistance to BRAF Inhibition in Melanomas
- (2011) David B. Solit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
- (2011) F Xing et al. ONCOGENE
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
- (2010) B. Comin-Anduix et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
- (2010) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
- (2010) U. Banerji et al. CLINICAL CANCER RESEARCH
- Unusual Presentation of Large-Cell Poorly Differentiated Neuroendocrine Carcinoma of the Epiglottis
- (2010) Kevin J. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS and BRAF: drug targets and predictive biomarkers
- (2010) Efsevia Vakiani et al. JOURNAL OF PATHOLOGY
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
- (2010) F M Kaplan et al. ONCOGENE
- PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
- (2010) Ruth Halaban et al. Pigment Cell & Melanoma Research
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
- (2009) Nathalie Dhomen et al. CANCER CELL
- Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma
- (2009) M. W. VanBrocklin et al. CANCER RESEARCH
- Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
- (2009) R. K. Amaravadi et al. CLINICAL CANCER RESEARCH
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation
- (2009) Bin Zheng et al. MOLECULAR CELL
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
- c-Kit mutants require hypoxia-inducible factor 1α to transform melanocytes
- (2009) G Monsel et al. ONCOGENE
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis
- (2008) Yanhua Zhao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
- (2008) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
- (2008) Mark S. Cragg et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
- Mutant B-RAF mediates resistance to anoikis via Bad and Bim
- (2008) K Boisvert-Adamo et al. ONCOGENE
- Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
- (2008) Robert A. Cartlidge et al. Pigment Cell & Melanoma Research
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now